

A national program to scale-up point-of-care testing for hepatitis C infection


WA Health STI and BBV Quarterly Forum, 11th June 2025

Professor Jason Grebely
Head, Hepatitis C and Drug Use Research Group
Viral Hepatitis Clinical Research Program
The Kirby Institute, UNSW Sydney



This program is funded by the Australian Government Department of Health

Finger-stick testing for current hepatitis C infection




- First study globally to evaluate a finger-stick test (venous cartridge) for current HCV (2 hours)¹
- Data used by Cepheid to develop a finger-stick version of this test that we evaluated (1 hour)², with good technical accuracy (100% sensitivity/specificity)²⁻³
- “Game-changer” – Enables single-visit diagnosis and treatment, increases testing acceptability, and reduces loss to follow-up
- Led clinical studies demonstrated improved time to treatment (6 vs 99 days in prisons)⁴ and proportion initiating treatment (93% vs 22% in prisons; 81% in needle/syringe programs)⁴⁻⁵



Point-of-care HCV RNA testing to enhance care



Initial
testing/diagnosis




SVR
confirmation




Post-treatment monitoring
for HCV reinfection

Single-visit strategies to improve testing



**Point-of-care HCV RNA and
diagnosis (Health care worker)**

**Point-of-care HCV RNA
(high HCV prevalence setting)**




**Rapid anti-HCV antibody test,
point-of-care HCV RNA and
diagnosis (Health care worker)**

**Rapid HCV antibody testing with
reflex point-of-care HCV RNA
(low HCV prevalence setting)**

Point-of-care antibody testing should facilitate scale-up

- Point-of-care antibody testing is less expensive than HCV RNA testing
 - \$10 vs. \$60 per test
- Point-of-care antibody testing is a lower complexity test (easier to train operators)
- Improved acceptability of point-of-care antibody testing among patients/providers (RNA-60 mins)
 - Negative HCV antibody test (1-20 mins)
 - Positive HCV antibody test (1-5 mins)
- Improved efficiency of the GeneXpert platform
 - Limit of 4 tests per hour (one per module for a 4-module machine)
 - Use HCV antibody testing to triage patient samples for high-intensity testing campaigns

How did the Australian Hepatitis C Point-of-care Testing program get established?




Australian Government
Department of Health

Australian Hepatitis C Point-of-Care Testing Program



- Community Site
- Prison Site



- 65 sites nationally with 50-60,000 people tested (2021-24)
- Drug treatment clinics, NSPs, prisons, mental health, mobile outreach models, homelessness services, Aboriginal Community Controlled Health Organisations
- Testing for anyone at risk of HCV or attending service
- Point-of-care testing for HIV and HBsAg
- Program includes:
 - 1) SOPs, logistics, deployment, and set-up
 - 2) Training
 - 3) Quality assurance program
 - 4) IT/connectivity
 - 5) Research and evaluation framework

Finger stick point-of-care HCV antibody testing (1-5 minutes)




Finger stick point-of-care HCV RNA testing (60 minutes)




Program successes

115 sites



>400 testing locations





Program successes

- >430 operators have undergone training to date
- 28 high-intensity testing campaigns at 18 prisons (QLD, n=14; NSW, n=6; SA, n=2; VIC, n=2)
- 44,226 HCV point-of-care tests and 4,158 people with current HCV
- 2,893 people treated of 4,158 evaluable (36% retreatment)
 - Treatment uptake (within 12 weeks): 70%
 - 60% in community
 - 80% in prison
- 10% of all HCV treatment in Australia
 - 23% in Queensland




WA Study Sites

- Community Site
- Prison Site



Testing Locations



WA Community Sites



Site Name	Type	Service Type	Devices
PBHR Perth	Private	Mobile Outreach & NSP	2
PBHR Bunbury	Private	Mobile Outreach & NSP	2
Hepatitis WA	Private	Community Health & NSP	2
South Terrace Clinic (Fremantle SHS)	Public	Sexual Health & NSP	1
Pramana Medical	Private	Primary Health	1
Next Step Fremantle	Public	Drug Treatment	1
Next Step Innaloo	Public	Drug Treatment	1
Next Step East Perth	Public	Drug Treatment	1 (not yet received)
Plantagenet Medical	Private	Primary Health	1 (not yet received)

Total - 12

WA Prison Sites

Site Name	Type	Devices
Albany Regional Prison	Public	1
Bandyup Women's Prison	Public	1
Acacia Prison	Private	1
Eastern Goldfields Regional Prison	Public	1 (not yet received)

Total - 4

WA Operators Trained

Site Name	Operators Trained
PBHR Perth	8
PBHR Bunbury	4
Hepatitis WA	3
South Terrace Clinic (Fremantle SHS)	2 1 – Currently Training
Pramana Medical	3
Next Step Fremantle	2 1 – Currently Training
Next Step Innaloo	3
Next Step East Perth	3 – Currently Training
Plantagenet Medical	3 – Pending Training
Acacia Prison	4
Albany Regional Prison	1
Bandyup Women's Prison	1
Eastern Goldfields Regional Prison	2 – Currently Training

Total:
31 Complete
10 Pending

WA Testing numbers (up to June 2025)

	Community	Prison
# Tests performed	1607	13
# People tested	1251	12
# HCV Ab tests performed	752	0
# HCV Ab detectable tests	97	-
# HCV RNA tests performed	855 846 (POC) 9 (VP)	13 (POC)
# HCV RNA detectable	205 Tests 174 People (14%)	3

Patient Demographics (WA Community)

	Community
Aboriginal and/or Torres Strait Islander	350 (28%)
Male	806 (64%)
Age mean (SD)	44 (11)
Homeless	553 (44%)
On OAT Currently	97 (8%)
On OAT Previously	170 (13%)
Never	990 (79%)
History of HCV infection	496 (40%)
History of HCV treatment	303 (70%)
Previous injecting drug history n (%)	1017 (81%)
Yes, but not in the last 6 months	180 (14%)
Yes, in the last 6 months but not in the last 30 days	108 (9%)
Yes, in the last 30 days	729 (58%)

Treatment numbers (up to May 2025)

Total WA Sites	Treatment Uptake (%) by Wk 12	Treatment Uptake (%) Ever	Confirmed LTFU
Community	43%	47%	40%

Ongoing program challenges

**Delivery of results
into patient records
and health
departments**

**How to streamline
training further?**

**Paperwork,
survey, and
data entry**

**Integrated
testing (beyond
HCV, HIV & HBV)**

**Programme funding
does not include
staffing costs**

**Clinician education
of testing/treatment
guidelines**

**Integration of point-of-
care testing into
business as usual**

**Strategies to
enhance HCV
treatment uptake**



This program is funded by the Australian Government Department of Health

*All **participants** who have contributed their time and data to our study, and:*

Kirby Team:

David Silk
Simon Comben
Stephanie Davey
Samira Hosseini Hooshyar
Jake Abbott
Keren Smart
Rebecca Henry
Maria Martinez
Ineke Shaw
Rachel Caldwell
Tristan Franks
Lisa Coulson
Evan Cunningham
Louise Causer
Rebecca Guy
Gregory Dore
Marianne Byrne

Marianne Martinello
Andrew Lloyd
Yumi Sheehan
Tanya Applegate
Richard Gray
Behzad Hajarizadeh
Lise Lafferty
Alison Marshall
Sophy Shih
Elise Tu

Virginia Wiseman
Kirsty Smith
Belinda Hengel

International Centre for Point-of-Care Testing Team:

Susan Matthews
Corey Markus
John Hepburn
Jae Williams
Larissa Kahl
Brittany Whitford